The tuberculosis challenge in a rural South African HIV programme

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Houlihan, Catherine F ^a   Mutevedzi, Portia C ^a   Lessells, Richard J ^a   Cooke, Graham S ^a,b   Tanser, Frank C ^a   Newell, Marie Louise ^a,c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREVALENCE; RURAL AREA; SOUTH AFRICA; TUBERCULOSIS; VIRUS LOAD; ADOLESCENT; AIDS RELATED COMPLEX; RISK FACTOR; RURAL POPULATION; SEX DIFFERENCE;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; PREVALENCE; RISK FACTORS; RURAL POPULATION; SEX FACTORS; SOUTH AFRICA; TUBERCULOSIS; VIRAL LOAD; YOUNG ADULT;

EID: 77949473085     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-23     Document Type: Article

References (38)

1. Report on the global AIDS epidemic. 2008, Geneva: UNAIDS.
2. WHO Global Tuberculosis Control Report 2009 surveillance planning financing. 2009, WHO.
3. Barnighausen T, Tanser F, Gqwede Z, Mbizana C, Herbst K, Newell ML. High HIV incidence in a community with high HIV prevalence in rural South Africa: findings from a prospective population-based study. AIDS 2008, 22:139-144. 10.1097/QAD.0b013e3282f2ef43, 18090402.
4. Department of Health (Directorate: Health Systems Research and Epidemiology). Notification System. Pretoria. Downloaded from Health Systems Trust. , http://www.hst.org.za/healthstats/16/data
5. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368:1575-1580. 10.1016/S0140-6736(06)69573-1, 17084757.
6. Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. J Infect Dis 2007, 196(Suppl 3):S482-490. 10.1086/521121, 18181698.
7. Lowrance DW, Makombe S, Harries AD, Shiraishi RW, Hochgesang M, Aberle-Grasse J, et al. A public health approach to rapid scale-up of antiretroviral treatment in Malawi during 2004-2006. J Acquir Immune Defic Syndr 2008, 49:287-293. 10.1097/QAI.0b013e3181893ef0, 18845953.
8. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. Aids 2006, 20:1605-1612. 10.1097/01.aids.0000238406.93249.cd, 16868441.
9. Tanser F, Hosegood V, Benzler J, Solarsh G. New approaches to spatially analyse primary health care usage patterns in rural South Africa. Trop Med Int Health 2001, 6:826-838. 10.1046/j.1365-3156.2001.00794.x, 11679131.
10. Welz T, Hosegood V, Jaffar S, Batzing-Feigenbaum J, Herbst K, Newell ML. Continued very high prevalence of HIV infection in rural KwaZulu-Natal, South Africa: a population-based longitudinal study. AIDS 2007, 21:1467-1472. 10.1097/QAD.0b013e3280ef6af2, 17589193.
11. South Africa National Department of Health. National Antiretroviral Treatment Guidelines. 2004, First., http://www.doh.gov.za/docs/facts-f.html
12. The South Africa National Tuberculosis Control Programme. Practical Guidelines. 2004, , http://www.kznhealth.gov.za/chrp/documents/Guidelines/Guidelines%20Natio nal/Tuberculosis/SA%20TB%20Guidelines%202004.pdf
13. STATA Statistical Software release 10: survival analysis and epidemiological tables: A Stata Press Publication, StataCorp LP, College Station, Texas.
14. Kulldorff M. SaTScan v7.0: Software for the spatial and space-time statistics. 2006, National Cancer Institute., http://www.satscan.org
15. Huang L, Kulldorff M, Gregorio D. A spatial scan statistic for survival data. Biometrics 2007, 63:109-118. 10.1111/j.1541-0420.2006.00661.x, 17447935.
16. Kulldorff M, Heffernan R, Hartman J, Assuncao R, Mostashari F. A space-time permutation scan statistic for disease outbreak detection. PLoS Med 2005, 2:e59. 10.1371/journal.pmed.0020059, 548793,548793, 15719066.
17. Westreich D. Pulmonary tuberculosis at initiation of HAART and mortality: experience from the Themba Lethu Clinical Cohort, Johannesburg, South Africa. HIV Implementers Meeting 2008,
18. Makombe SD, Harries AD, Yu JK, Hochgesang M, Mhango E, Weigel R, et al. Outcomes of tuberculosis patients who start antiretroviral therapy under routine programme conditions in Malawi. Int J Tuberc Lung Dis 2007, 11:412-416.
19. Moore D, Liechty C, Ekwaru P, Were W, Mwima G, Solberg P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 2007, 21:713-719. 10.1097/QAD.0b013e328013f632, 17413692.
20. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR, Hopewell PC. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992, 326:231-235.
21. Shafer RW, Edlin BR. Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade. Clin Infect Dis 1996, 22:683-704.
22. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008, 8:516-523. 10.1016/S1473-3099(08)70184-1, 2804035, 18652998.
23. Ouattara E, Messou E, Gabillard D, Seyler C, Anglaret X. Are a past history of tuberculosis and WHO clinical stage associated with incident tuberculosis in adults receiving antiretroviral therapy?, reply to Lawn et al. AIDS 2007, 21:389-390. 10.1097/QAD.0b013e328011f964, 17255756.
24. Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med 2005, 172:123-127. 10.1164/rccm.200410-1342OC, 15805184.
25. Cruciani M, Malena M, Bosco O, Gatti G, Serpelloni G. The impact of human immunodeficiency virus type 1 on infectiousness of tuberculosis: a meta-analysis. Clin Infect Dis 2001, 33:1922-1930. 10.1086/324352, 11692305.
26. Lin J, Sattar AN, Puckree T. An alarming rate of drug-resistant tuberculosis at Ngwelezane Hospital in northern KwaZulu Natal, South Africa. Int J Tuberc Lung Dis 2004, 8:568-573.
27. Sloan D. Tuberculosis management and drug resistance in Hlabisa Hospital, KwaZulu-Natal. [Abstract 1515]. The Federation of Infection Societies Conference. Cardiff 2006,
28. Brinkhof MW, Egger M, Boulle A, May M, Hosseinipour M, Sprinz E, et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007, 45:1518-1521. 10.1086/522986, 17990236.
29. Van Rie A. Risk factors for incident pulmonary tuberculosis after the initiation of HAART in the Themba Lethu Clinical Cohort, Johannesburg, South Africa [Abstract TS 82267-20]. HIV Implementers Meeting, Kampala, Uganda 2008,
30. Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, et al. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol 2008, 168:532-540. 10.1093/aje/kwn179, 18663213.
31. Meintjes G, Schoeman H, Morroni C, Wilson D, Maartens G. Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: a cross-sectional study. BMC Infect Dis 2008, 8:72. 10.1186/1471-2334-8-72, 2413241, 18501019.
32. MacPherson P, Moshabela M, Martinson N, Pronyk P. Mortality and loss to follow-up among HAART initiators in rural South Africa. Trans R Soc Trop Med Hyg 2009, 103:588-593. 10.1016/j.trstmh.2008.10.001, 19012940.
33. Wallrauch C, Baernighausen T, Heller T, Houlihan C, Newell M. The white and the three-letter plague: integration of TB and HIV care in sub-Saharan Africa. Future HIV Therapy 2008, 2:437-451.
34. Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci USA 2006, 103:7042-7047. 10.1073/pnas.0600349103, 1459015, 16632605.
35. Badal-Faesen. Impact of Tuberculosis on HIV viral load response in patients accessing antiretroviral treatment at Themba Lethu Clinic, South Africa. CROI 2008,
36. Tanser F, Barnighausen T, Cooke GS, Newell ML. Localized spatial clustering of HIV infections in a widely disseminated rural South African epidemic. Int J Epidemiol 2009, 38:1008-1016. 10.1093/ije/dyp148, 19261659.
37. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002, 359:2059-2064. 10.1016/S0140-6736(02)08904-3, 12086758.
38. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 2005, 19:1113-1124. 10.1097/01.aids.0000176211.08581.5a, 15990564.